|Bid||30.30 x 1100|
|Ask||34.16 x 800|
|Day's Range||30.43 - 32.06|
|52 Week Range||26.85 - 68.03|
|Beta (5Y Monthly)||0.98|
|PE Ratio (TTM)||10.65|
|Earnings Date||Jul 27, 2022 - Aug 01, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||44.33|
Subscribe to Yahoo Finance Plus to view Fair Value for EBS
The White House will sharply expand availability of monkeypox vaccines while rolling out more testing capacity for the virus.
The FDA accepts Emergent's (EBS) BLA seeking approval for its new anthrax vaccine, AV7909. A decision is expected in April next year.
Emergent BioSolutions Inc. said Friday the U.S. Food and Drug Administration has accepted for review its application for approval of its anthrax vaccine. Dubbed AV7909, the vaccine is aimed at people aged 18 through 65 years who have been exposed to anthrax for use along with recommended antibacterial drugs. A decision is expected by April of 2023. "As we progress toward licensure of AV7909, which is designed to follow a two-dose immunization schedule and to elicit a faster immune response, we r